Tokyo, Dec. 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060098) titled 'Effectiveness and safety of home-visiting chemotherapy for advanced cancer patients with difficulty receiving hospital-based chemotherapy' on Dec. 16.
Study Type:
Observational
Primary Sponsor:
Institute - Tendai Medical Corporation, Tsuruta Clinic
Condition:
Condition - Unresectable advanced cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To retrospectively evaluate the effectiveness and safety of home-visiting chemotherapy provided as part of routine clinical practice in patients with unresectable advanced cancer not considered eligible for hospital-based chemotherapy, and to identify prognostic factors.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1.Age 20 years or older at the start of treatment.
2.Diagnosis of malignancy based on histology, cytology, or imaging studies.
3.Clinical diagnosis of unresectable advanced cancer.
4.Difficulty in attending hospital-based chemotherapy, with prior clinical decision for palliative care or inability to receive outpatient chemotherapy.
5.First home-visit medical care at the study institution between July 1, 2023 and March 31, 2025.
Key exclusion criteria - 1.Patients expressing refusal to participate through the opt-out process.
2.Patients considered inappropriate for the study by the principal investigator.
Target Size - 142
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2023 Year 06 Month 30 Day
Date of IRB - 2025 Year 08 Month 27 Day
Anticipated trial start date - 2023 Year 07 Month 01 Day
Last follow-up date - 2025 Year 10 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068732
Disclaimer: Curated by HT Syndication.
